Associated risk factors of quality of life in children receiving cancer treatment over the past decade: A systematic review and meta-analysis.

J Pediatr NursJun 6, 2026 (epub)
Clinical ResearchOncology (Medical)Pediatrics

Huilu Yao, Hongxiu Wang, Ying Xiao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined risk factors affecting quality of life (QoL) in pediatric cancer patients, analyzing 21 studies with 1884 participants aged 0 to 19 years. Key findings revealed that receiving radiotherapy and/or chemotherapy was associated with a significant impairment in QoL (SMD = 0.90, p < 0.00001).

Key findings

  • Receiving radiotherapy and/or chemotherapy was linked to poorer QoL (SMD = 0.90, p < 0.00001).
  • Higher cancer risk correlated with reduced QoL (SMD = 0.71, p = 0.002).
  • Poor physical functioning was associated with lower QoL (SMD = 0.79, p < 0.00001).
  • Parental divorce/separation negatively impacted QoL (SMD = 0.92, p = 0.0001).

Why it matters

Understanding the risk factors that impair QoL in children undergoing cancer treatment is crucial for developing targeted interventions. This knowledge can help clinicians address the multifaceted challenges these patients face, ultimately improving their overall well-being.

Source

PubMed · PMID 42247856

Published in J Pediatr Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.